Physician profile
Michael D Share
NPI 1528333879
$1,986.09
in general payments reported to CMS, 2019-2025
23 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $62.96 · 2021: $80.36 · 2022: $245 · 2023: $215 · 2024: $317 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936 · Education: $20.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.84 |
| Education | $20.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $489.21 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $225.36 | 2019-2025 | |
| Medtronic, INC. | $221.93 | 2025 | Affera Mapping System, Endurant Iis |
| Boston Scientific Corporation | $188.05 | 2019-2024 | Ekosonic, Ranger |
| Amarin Pharma, INC. | $141.89 | 2019 | |
| Pfizer INC. | $126.27 | 2019-2023 | |
| Heartflow, INC. | $76.43 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $56.45 | 2019-2025 | Camzyos, Eliquis |
| Ge Healthcare | $48.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.96 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $44.35 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $39.92 | 2022-2023 | Opsumit |
| Abiomed | $36.44 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $34.15 | 2024 | Wainua |
| Lexicon Pharmaceuticals, INC. | $29.87 | 2023 | Inpefa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $28.92 | 2024 | Evkeeza |
| Edwards Lifesciences Corporation | $24.54 | 2021 | |
| Scpharmaceuticals INC. | $23.83 | 2023 | |
| Genzyme Corporation | $22.31 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.71 | 2024 | Jardiance |
| Intercept Pharmaceuticals, INC. | $21.12 | 2019 | |
| Esperion Therapeutics, INC. | $21.11 | 2025 | Nexletol |
| Romark Laboratories, Lc | $19.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Share listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.